SCHEMBL15613190

SCHEMBL15613190

O=C(O)c1ccc2c(=O)n(CCc3c[nH]cn3)c(=S)[nH]c2c1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ PKM P14618 1/20 0.51
▸ ALDH1A1 P00352 9/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ HPGD P15428 4/20 0.48
▸ HTT P42858 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48
▸ GAA P10253 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2911095 0.75 ALDH1A1 (0.65) KDM4EKMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL15550280 0.74 NPC1 (0.58) KDM4EKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL22281511 0.74 KMT2A (0.67) KDM4EKMT2APKMALDH1A1SMN1; SMN2
SCHEMBL5652363 0.73 SMN1; SMN2 (0.76) KDM4EKMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL2917327 0.72 KMT2A (0.58) KDM4EKMT2APKMALDH1A1SMN1; SMN2
SCHEMBL2730278 0.70 KDM4E (0.65) KDM4EKMT2APKMALDH1A1SMN1; SMN2
SCHEMBL2915423 0.69 KDM4E (0.71) KDM4EKMT2AALDH1A1SMN1; SMN2HTT
SCHEMBL2915065 0.68 KDM4E (0.65) KDM4EKMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL2900654 0.67 KDM4E (0.64) KDM4EKMT2AALDH1A1SMN1; SMN2HTT
SCHEMBL4251761 0.67 KDM4E (0.83) KDM4EKMT2APKMALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170348295-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA SIRGA ADVANCED BIOPHARMA INC (US) 2017-12-07 — — US disclosed
US-20170348295-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA SIRGA ADVANCED BIOPHARMA INC (US) 2017-12-07 — — US disclosed
US-9775835-B2 Small molecule inhibitors of viral protein interactions with human t-RNA SIRGA ADVANCED BIOPHARMA, INC. (US) 2017-10-03 — — US disclosed
US-9775835-B2 Small molecule inhibitors of viral protein interactions with human t-RNA SIRGA ADVANCED BIOPHARMA, INC. (US) 2017-10-03 — — US disclosed
US-20150190384-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA SIRGA ADVANCED BIOPHARMA, INC. (US) 2015-07-09 — — US disclosed
US-20150190384-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA SIRGA ADVANCED BIOPHARMA, INC. (US) 2015-07-09 — — US disclosed
WO-2014025749-A2 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA SIRGA ADVANCED BIOPHARMA, INC. (US) 2014-02-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348295-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA NSUN3, TARBP1, TRDMT1 KDM4E 2424/4885KMT2A 2508/4885PKM 4022/4885
US-20150190384-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA NSUN3, TARBP1, TRDMT1 KDM4E 2593/4885KMT2A 2752/4885PKM 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback